Literature DB >> 18777591

Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Avi Levin1, Oren Shibolet.   

Abstract

Ulcerative colitis and Crohn's disease are chronic relapsing-remitting inflammatory processes of the intestinal tract. The etiology of these diseases is currently unknown. However, inflammation is hypothesized to result from inappropriate activation of mucosal immunity by luminal antigens in genetically susceptible individuals. Toll-like receptors (TLRs) are a family of transmembrane proteins that act as microbial pattern recognition receptors. They are crucial initiators of innate immune responses. The role of TLRs in the pathogenesis of inflammatory bowel disease (IBD) has not been fully elucidated. In this review, we aim to analyze the available data connecting individual TLRs to intestinal inflammation and IBD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777591      PMCID: PMC2744004          DOI: 10.3748/wjg.14.5149

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  56 in total

1.  Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation.

Authors:  Sang Hoon Rhee; Eunok Im; Martin Riegler; Efi Kokkotou; Michael O'brien; Charalabos Pothoulakis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

Review 2.  Toll-like receptors in innate immunity.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Int Immunol       Date:  2005-01       Impact factor: 4.823

3.  Double blind, placebo controlled trial of metronidazole in Crohn's disease.

Authors:  L Sutherland; J Singleton; J Sessions; S Hanauer; E Krawitt; G Rankin; R Summers; H Mekhjian; N Greenberger; M Kelly
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Characteristics of intestinal dendritic cells in inflammatory bowel diseases.

Authors:  Ailsa L Hart; Hafid Omar Al-Hassi; Rachael J Rigby; Sally J Bell; Anton V Emmanuel; Stella C Knight; Michael A Kamm; Andrew J Stagg
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation.

Authors:  Florian Obermeier; Nadja Dunger; Ulrike G Strauch; Claudia Hofmann; Andre Bleich; Nicole Grunwald; Hans J Hedrich; Elisabeth Aschenbrenner; Brigitte Schlegelberger; Gerhard Rogler; Jürgen Schölmerich; Werner Falk
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

6.  Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.

Authors:  Kyoko Katakura; Jongdae Lee; Daniel Rachmilewitz; Gloria Li; Lars Eckmann; Eyal Raz
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

7.  In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis.

Authors:  F Obermeier; U G Strauch; N Dunger; N Grunwald; H C Rath; H Herfarth; J Schölmerich; W Falk
Journal:  Gut       Date:  2005-05-05       Impact factor: 23.059

8.  A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.

Authors:  Madeline M Fort; Afsaneh Mozaffarian; Axel G Stöver; Jean da Silva Correia; David A Johnson; R Thomas Crane; Richard J Ulevitch; David H Persing; Helle Bielefeldt-Ohmann; Peter Probst; Eric Jeffery; Steven P Fling; Robert M Hershberg
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

9.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

Review 10.  Experimental models to study molecular mechanisms underlying intestinal inflammation.

Authors:  C O Elson; Y Cong; S Brandwein; C T Weaver; R P McCabe; M Mähler; J P Sundberg; E H Leiter
Journal:  Ann N Y Acad Sci       Date:  1998-11-17       Impact factor: 5.691

View more
  14 in total

1.  Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis.

Authors:  Fabio Alessandro Facchini; Davide Di Fusco; Simona Barresi; Andrea Luraghi; Alberto Minotti; Francesca Granucci; Giovanni Monteleone; Francesco Peri; Ivan Monteleone
Journal:  Eur J Clin Pharmacol       Date:  2020-01-25       Impact factor: 2.953

2.  Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis.

Authors:  I J J Claes; Sarah Lebeer; C Shen; T L A Verhoeven; E Dilissen; G De Hertogh; D M A Bullens; J L Ceuppens; G Van Assche; S Vermeire; P Rutgeerts; J Vanderleyden; S C J De Keersmaecker
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

3.  The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5.

Authors:  Clett Erridge; Sylvia H Duncan; Stefan Bereswill; Markus M Heimesaat
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

4.  Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Authors:  Wei Dou; Jingjing Zhang; Aning Sun; Eryun Zhang; Lili Ding; Subhajit Mukherjee; Xiaohui Wei; Guixin Chou; Zheng-Tao Wang; Sridhar Mani
Journal:  Br J Nutr       Date:  2013-03-18       Impact factor: 3.718

5.  Succinylated chitosan derivative has local protective effects on intestinal inflammation.

Authors:  Hyesun Hyun; Seika Hashimoto-Hill; Myunghoo Kim; Michael D Tsifansky; Chang H Kim; Yoon Yeo
Journal:  ACS Biomater Sci Eng       Date:  2017-06-05

6.  IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4.

Authors:  Xiaowei Chen; Wenwen Sun; Risheng Lin; Zhiming Huang; Weichang Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

7.  Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis.

Authors:  Wei-Lian Bao; Qibiao Wu; Bin Hu; Dongdong Sun; Shengnan Zhao; Xiaoyan Shen; Haibo Cheng; Weixing Shen
Journal:  Int J Nanomedicine       Date:  2021-01-13

Review 8.  Toll-like receptor activation by helminths or helminth products to alleviate inflammatory bowel disease.

Authors:  ShuMin Sun; XueLin Wang; XiuPing Wu; Ying Zhao; Feng Wang; XiaoLei Liu; Yanxia Song; ZhiLiang Wu; MingYuan Liu
Journal:  Parasit Vectors       Date:  2011-09-27       Impact factor: 3.876

9.  Antimicrobial Peptide Epinecidin-1 Modulates MyD88 Protein Levels via the Proteasome Degradation Pathway.

Authors:  Bor-Chyuan Su; Jyh-Yih Chen
Journal:  Mar Drugs       Date:  2017-11-16       Impact factor: 5.118

10.  Anti-inflammatory effects of the nicotinergic peptides SLURP-1 and SLURP-2 on human intestinal epithelial cells and immunocytes.

Authors:  Alex I Chernyavsky; Valentin Galitovskiy; Igor B Shchepotin; Sergei A Grando
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.